Pathology consultation on the diagnosis and treatment of thrombotic microangiopathies (TMAs)

American Journal of Clinical Pathology

Volumn 145, Issue 2, 2016, Pages 158-165

  Williams, Lance A ^a   Marques, Marisa B ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Hemolytic uremic syndrome (HUS); Microangiopathic hemolytic anemia (MAHA); Thrombotic microangiopathy (TMA); Thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN; ECULIZUMAB; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RITUXIMAB; TICLOPIDINE; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ANEMIA; BLOOD ANALYSIS; BLOOD CELL COUNT; BLOOD SAMPLING; CASE REPORT; CONSULTATION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE CONTROL; DISEASE SEVERITY; FEMALE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; LOW BACK PAIN; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; TREATMENT OUTCOME; URINALYSIS; YOUNG ADULT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; HEMOLYTIC-UREMIC SYNDROME; PATIENT REFERRAL; PLASMA EXCHANGE; PREGNANCY; PUERPERIUM; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PLASMA EXCHANGE; POSTPARTUM PERIOD; PREGNANCY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REFERRAL AND CONSULTATION; THROMBOTIC MICROANGIOPATHIES; YOUNG ADULT;

EID: 84959325741     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/AJCP/AQV086     Document Type: Review

References (67)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc. 1924;24:21-24.
2. Gasser VC, Gautier E, Steck A, et al. Hamolytisch-urami-sche syndrom: bilaterale nierenrindennekrosen bei akuten erworbenen hamolytischen anamien. Schweiz Med Wochenschr. 1955;85:905-909.
3. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangi-opathy, hemolytic uremic syndrome, and thrombotic throm-bocytopenic purpura. Kidney Int. 2001;60:831-846.
4. Kempton LC. Thrombotic thrombocytopenic purpura. In: BH Shaz, et al., eds. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. 2nd ed. London, UK: Elsevier; 2013:676.
5. Bobba RK, Doll DC. Platelet satellitism as a cause of spurious thrombocytopenia. Blood. 2012;119:4100.
6. George JN. How I treat patients with thrombotic thrombocy-topenic purpura: 2010. Blood. 2010;116:4060-4069.
7. Burns ER, Lou Y, Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol. 2004;75:18-21.
8. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with throm-botic thrombocytopenic purpura. J Clin Apher. 1998;13:16-19.
9. Kappler S, Ronan-Bentle S, Graham A. Thrombotic micro-angiopathies (TTP, HUS, HELLP). Emerg Med Clin North Am. 2014;32:649-671.
10. Al-Nouri ZL, Reese JA, et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015;125:616-618.
11. Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10:1-12.
12. Park YA, Waldrum MR, Marques MB. Platelet count and prothrombin time help distinguish thrombotic thrombocyto-penic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. Am J Clin Pathol. 2010;133:460-465.
13. Neame PB, Hirsh J, Browman G, et al. Thrombotic thrombo-cytopenic purpura: a syndrome of intravascular platelet consumption. Can Med Assoc J. 1976;114:1108-1112.
14. Bendapudi PK, Li A, Hamdan A, et al. Derivation and prospective validation of a predictive score for the rapid diagnosis of thrombotic thrombocytopenic purpura: the Plasmic score. Blood. 2014;124:21.
15. Griffin D, Al-Nouri ZL, Muthurajah D, et al. First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur? Transfusion. 2013;53:235-237.
16. George JN. Clinical practice: thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927-1935.
17. Wu N, Liu J, Yang S, et al. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic throm-bocytopenic purpura. Transfusion. 2015;55:18-24.
18. Reese JA, Muthurajah DS, Kremer-Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic pur-pura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013;60:1676-1682.
19. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombo-cytopenic purpura. Nature. 2001;413:488-494.
20. Sadler JE. Von Willebrand factor, ADAMTS13, and throm-botic thrombocytopenic purpura. Blood. 2008;112:11-18.
21. Laszik ZG, Silva FG. Hemolytic-uremic syndrome, throm-botic thrombocytopenic purpura, and systemic sclerosis (systemic scleroderma). In: JC Jennett, JL Olson, MM Schwartz, et al, eds. Heptinstall's Pathology of the Kidney. 5th ed. Philadelphia, PA: Lippincott-Raven; 1998:1003.
22. Hosler GA, Cusomano AM, Hutchins GM. Thrombotic throm-bocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. Arch Pathol Lab Med. 2003;127:834-839.
23. Vesely SR, George JN, Lammle B, et al. ADAMTS13activity in thrombotic thrombocytopenic purpurahemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-68.
24. Camilleri RS, Scully M, Thomas M, et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost. 2012;10:1792-1801.
25. Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9(suppl 1):283-301.
26. Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Program. 2004;407-423.
27. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142:819-826.
28. Amorosi E, Ultmann J. Thrombotic thrombocytopenic pur-pura: report of 16 cases and review of the literature. Medicine. 1966;45:139.
29. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-397.
30. Booth KK, Terrell DR, Vesely SK, et al. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011;86:743-751.
31. Kremer Hovinga JA, Vesely SK, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500-1511.
32. Coppo P, Bengoufa D, Veyradier A, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine. 2004;83:233-244.
33. Studt JD, Kremer Hovinga JA, Antoine G, et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood. 2005;105:542-544.
34. George JN. Forecasting the future for patients with hereditary TTP. Blood. 2012;120:243-244.
35. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107:528-534.
36. Nguyen QV, Descombes E. Etiology-based classification of hemolytic uremic syndrome/thrombotic thrombocyto-penic purpura: what about hemolytic uremic syndrome associated with urinary tract infections? Kidney Int. 2007;71:466.
37. Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008;99:1019-1029.
38. George JN. Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis. Thromb Haemost. 2008;99:987-988.
39. Böhm M, Betz C, Miesbach W, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol. 2005;129:644-652.
40. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis. J Clin Apher. 2013;28:145-284.
41. Sarode R, Bandarenko N, Brecher ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2014;29:148-167.
42. Bandarenko N, Brecher ME. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher. 1998;13:133-141.
43. Coppo P, Bussel A, Charrier S, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine. 2003;82:27-38.
44. Ziman A, Mitri M, Klapper E, et al. Combination vincristine and plasma exchange as initial therapy in patients with throm-botic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion. 2005;45:41-49.
45. Cataland SR, Jin M, Zheng XL, et al. An evaluation of cyclo-sporine alone for the treatment of early recurrences of throm-botic thrombocytopenic purpura. J Thromb Haemost. 2006;4:1162-1164.
46. Cataland SR, Jin M, Ferketich AK, et al. An evaluation of cyclosporine and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocy-topenic purpura. Br J Haematol. 2007;136:146-149.
47. Goyal J, Adamski J, Lima JL, et al. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab. J Clin Apher. 2013;28:390-394.
48. Briones MA. Thrombotic Thrombocytopenic Purpura. In: BH Shaz, et al, eds. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. 2nd ed. London, UK: Elsevier; 2013:669-674.
49. Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol Adv Applications. 2011;3:5-12.
50. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60-90.
51. Atkinson JP, Goodship THJ. Complement factor H and the hemolytic uremic syndrome. J Exp Med. 2007;204:1245-1248.
52. Skerka C, Jozsi M, Zipfel PF, et al. Autoantibodies in hemo-lytic-uremic syndrome (HUS). Thromb Hemost. 2009;101:227-232.
53. Sellier-Leclerc A-L, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392-2400.
54. Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715-1726.
55. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-1687.
56. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CF, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279.
57. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169-2181.
58. Zuber J, Fakhouri F, Roumenina LT, et al; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643-657.
59. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365:1771-1780.
60. Karpac CA, Li X, Terrell DR, et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol. 2008;141:696-707.
61. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-1086.
62. Kehl KS, Havens P, Behnke CE, et al. Evaluation of the premier EHEC assay for detection of Shiga toxin-producing Escherichia coli. J Clin Microbiol. 1997;35:2051-2054.
63. Gerritzen A, Wittke JW, Wolff D. Rapid and sensitive detection of Shiga toxin-producing Escherichia coli directly from stool samples by real-time PCR in comparison to culture, enzyme immunoassay and Vero cell cytotoxicity assay. Clin Lab. 2011;57:993-998.
64. Vallières E, Saint-Jean M, Rallu F. Comparison of three different methods for detection of Shiga toxin-producing Escherichia coli in a tertiary pediatric care center. J Clin Microbiol. 2013;51:481-486.
65. Dundas S, Murphy J, Soutar RL, et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet. 1999;354:1327-1330.
66. Colic E, Dieperink H, Titlestad K, et al. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet. 2011;378:1089-1093.
67. Kielstein JT, Beutel G, Fleig S, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemo-lytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 2012;27:3807-3815.